Dogwood Therapeutics Stock Price, News & Analysis

Dogwood Therapeutics (NASDAQ:DWTX) has reported its Q2 2025 financial results, highlighting progress in its Halneuron® Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company has enrolled 52 patients with a low discontinuation rate of 5.8%, suggesting good tolerability. The interim data readout remains on track for Q4 2025.

The company's pipeline includes Halneuron®, which has received FDA fast track designation for CINP treatment, and IMC-1 for Fibromyalgia. Financial results show R&D expenses of $2.5 million and a net loss of $3.8 million. With $13.4 million cash on hand, Dogwood has operational runway through Q1 2026.

Dogwood Therapeutics (NASDAQ:DWTX) has reached a significant milestone in its Phase 2b clinical trial for Halneuron®, enrolling the first 50 patients to evaluate the drug's effectiveness in treating Chemotherapy-Induced Neuropathic Pain (CINP). The trial, known as HALT-CINP, demonstrates promising early safety data with only a 6% discontinuation rate among the first 35 patients.

The study focuses on cancer patients with neuropathy from platinum or taxane-based chemotherapy, administering 8 daily subcutaneous doses over 14 days with a 28-day follow-up. The company remains on track for its Q4 2025 interim analysis of approximately 100 patients, with full results expected in mid-2026. The trial will be conducted across 25 U.S. sites, evaluating primary endpoints of safety and pain intensity reduction.

Dogwood Therapeutics (Nasdaq: DWTX), a development-stage biotech company focused on developing treatments for pain and fatigue-related disorders, will release its Q2 2025 financial results on Wednesday, August 13, 2025, before market open.

Dogwood Therapeutics (NASDAQ: DWTX), a development-stage biotech company focused on pain and fatigue-related disorders, announced its participation in the upcoming Sidoti Small-Cap Virtual Conference. CEO Greg Duncan will deliver a corporate overview presentation on Wednesday, June 11, 2025, at 9:15 AM ET. The conference runs from June 11-12, 2025, and Duncan will be available for one-on-one meetings with investors. The presentation will be accessible via webcast, and interested parties can register for the conference and schedule meetings through the provided links.

Dogwood Therapeutics (DWTX) reported Q1 2025 financial results and key developments. The company has begun dosing patients in its Halneuron® Phase 2b study for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025. The company's financial position includes $17.5M cash on hand, providing runway through Q1 2026, bolstered by a $4.8M stock raise and conversion of a $19.5M loan to equity by CK Life Sciences. Q1 2025 saw increased R&D expenses of $2.4M (up from $0.3M in Q1 2024) and G&A expenses of $2.0M (up from $1.0M). The net loss was $12.2M or $8.45 per share. The company regained Nasdaq compliance and maintains FDA fast track designation for Halneuron® in CINP treatment.

Dogwood Therapeutics (NASDAQ: DWTX) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman Greg Duncan will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com for registration.

Dogwood Therapeutics (DWTX) has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, following a notification of non-compliance received on November 15, 2024. The company submitted a compliance plan on December 27, 2024, and was granted until May 14, 2025, to meet the requirement.

The biopharmaceutical company, focused on developing medicines for pain and fatigue-related disorders, reports a strong cash position of $17.5 million as of Q1. DWTX is currently conducting a Phase 2b trial for Halneuron® in Chemotherapy Induced Neuropathic Pain, with interim data analysis planned for Q4 2025.

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced it believes it has regained compliance with Nasdaq's minimum stockholders’ equity requirement, as per Listing Rule 5550(b)(1). The company, focused on developing medicines for pain and fatigue-related disorders, has a strong cash position of $17.5 million with no debt as of Q1 end. On November 15, 2024, DWTX was notified it fell below the $2.5 million minimum equity requirement. A compliance plan was submitted on December 27, 2024, and Nasdaq granted an extension until May 14, 2025. Key transactions include a Debt Exchange and Cancellation Agreement with Conjoint, Inc., converting $19.9 million in debt to Series A-1 Non-Voting Convertible Preferred Stock, and a stock purchase agreement raising $4.8 million from institutional investors. As of March 31, 2025, DWTX had 1,911,128 shares of common stock outstanding.

Dogwood Therapeutics (NASDAQ: DWTX) has reported its Q4 and full-year 2024 financial results, highlighting significant developments in its pipeline. The company has begun dosing patients in the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathic Pain (CINP), with interim data expected in Q4 2025.

Financial highlights include a $19.5M debt-to-equity conversion by major shareholder CK Life Sciences, and a $4.8M common stock raise, extending operational runway through Q1 2026. The company reported a Q4 2024 net loss of $8.2M ($6.29 per share) compared to $1.1M in Q4 2023. Full-year 2024 net loss was $12.9M ($12.52 per share).

R&D expenses increased to $2.3M in Q4 2024 from $0.3M in Q4 2023, while G&A expenses rose to $5.2M from $0.8M. Cash position stands at $14.8M as of December 31, 2024.